» Articles » PMID: 10373754

[Vascular Endothelial Factor (VEGF): Therapeutic Angiogenesis and Vasculogenesis in the Treatment of Cardiovascular Disease]

Overview
Specialty General Medicine
Date 1999 Jun 22
PMID 10373754
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

The formation of new blood vessel is essential for a variety of physiological processes like embryogenesis and the female reproduction as well as pathological processes like tumor growth, wound healing and neovascularization of ischemic tissue. Vasculogenesis and angiogenesis are the mechanisms responsible for the development of the blood vessels. While angiogenesis refers to the formation of capillaries from pre-existing vessels in the embryo and adult organism, vasculogenesis, the development of new blood vessels from in situ differentiating endothelial cells, has been previously considered restricted to embryogenesis. Recent investigations, however, show the existence of endothelial progenitor cells (EPCs) in the peripheral blood of the adult and their participation in ongoing neovascularization. Molecular and cell-biological experiments suggest that different cytokines and growth factors have a stimulatory effect on these bone-marrow derived EPCs. Results with GM-CSF (granulocyte macrophage-colony stimulating factor) and VEGF (vascular endothelial growth factor) open a new insight into the clinical use of cytokines and in particular the use of growth factors in gene therapy. The administration via protein or plasmid-DNA for neovascularization seems to enhance both pathways, angiogenesis and vasculogenesis.

Citing Articles

Emergent biomarkers of residual cardiovascular risk in patients with low HDL-c and/or high triglycerides and average LDL-c concentrations: focus on HDL subpopulations, Oxidized LDL, adiponectin, and uric acid.

Mascarenhas-Melo F, Palavra F, Marado D, Sereno J, Teixeira-Lemos E, Freitas I ScientificWorldJournal. 2013; 2013:387849.

PMID: 24319364 PMC: 3835367. DOI: 10.1155/2013/387849.


Hematopoietic stem cells are pluripotent and not just "hematopoietic".

Ogawa M, LaRue A, Mehrotra M Blood Cells Mol Dis. 2013; 51(1):3-8.

PMID: 23453528 PMC: 3646972. DOI: 10.1016/j.bcmd.2013.01.008.


Cell therapy, a new standard in management of chronic critical limb ischemia and foot ulcer.

Prochazka V, Gumulec J, Jaluvka F, Salounova D, Jonszta T, Czerny D Cell Transplant. 2010; 19(11):1413-24.

PMID: 20529449 PMC: 5478382. DOI: 10.3727/096368910X514170.


[Therapeutically induced arteriogenesis in the brain. A new approach for the prevention of cerebral ischemia with vascular stenosis].

Busch H, Buschmann I, Schneeloch E, Bode C, Mies G, Hossmann K Nervenarzt. 2005; 77(2):215-20.

PMID: 16273341 DOI: 10.1007/s00115-005-1988-4.

References
1.
Baffour R, Berman J, Garb J, Rhee S, Kaufman J, Friedmann P . Enhanced angiogenesis and growth of collaterals by in vivo administration of recombinant basic fibroblast growth factor in a rabbit model of acute lower limb ischemia: dose-response effect of basic fibroblast growth factor. J Vasc Surg. 1992; 16(2):181-91. View

2.
Isner J, Takayuki A . Therapeutic angiogenesis. Front Biosci. 1998; 3:e49-69. DOI: 10.2741/a367. View

3.
Uchida Y, Nakamura F, Tomaru T, Kido H, Kamijo T, Sugimoto T . Salvage of infarcted myocardium by angiogenic action of basic fibroblast growth factor. Science. 1992; 257(5075):1401-3. DOI: 10.1126/science.1382313. View

4.
Risau W, Flamme I . Vasculogenesis. Annu Rev Cell Dev Biol. 1995; 11:73-91. DOI: 10.1146/annurev.cb.11.110195.000445. View

5.
Takahashi T, Kalka C, Masuda H, Chen D, Silver M, Kearney M . Ischemia- and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization. Nat Med. 1999; 5(4):434-8. DOI: 10.1038/7434. View